Mark G. Lebwohl
Mark G. Lebwohl is an American dermatologist and author who is Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology and the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai in New York City.Lebwohl's books include the book on dermatologic therapy, ''Treatment of Skin Disease'' (), as well as ''Atlas of the Skin and Systemic Disease'' (). He has authored more than 500 publications, multiple book chapters and has been named as one of New York Magazine’s “Best Doctors” every year since the inception of the annual list. Dr. Brian S. Kim is director of a Center for Neuroinflammation and Sensation named in Mark Lebwohl's honor at Icahn School of Medicine at Mount Sinai. Provided by Wikipedia
Showing 1 - 18 results of 18 for search 'Mark Lebwohl', query time: 0.04s
Refine Results
-
1
-
2
Stasis dermatitis: A challenging patient journey by Mark Lebwohl, Robert S. Kirsner, David J. Margolis, Benjamin Barankin, Takashi Hashimoto, Juliana M. Canosa, Amy Cha
Published 2023-12-01
Article -
3
-
4
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study by Andreas Pinter, Ahmed M. Soliman, Irina Pivneva, Roksana Ghanbariamin, Min Yang, Bang Truong, Luis Puig, Mark Lebwohl
Published 2024-05-01
Article -
5
Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry by Bruce Strober, Kristina Callis Duffin, Mark Lebwohl, Adam Sima, Jud Janak, Manish Patel, Huzefa Photowala, Vishvas Garg, Jerry Bagel
Published 2024-12-01
Article -
6
-
7
Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials by Saxon D. Smith, Alexandros Stratigos, Matthias Augustin, Jose Manuel Carrascosa, Susanne Grond, Elisabeth Riedl, Wen Xu, Himanshu Patel, Mark Lebwohl
Published 2023-06-01
Article -
8
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry by Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin H. Li, Thomas Eckmann, Baojin Zhu, William N. Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt
Published 2024-06-01
Article -
9
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis by Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, Andreas Pinter, Richard B. Warren, Luis Puig, Rhys Warham, Jérémy Lambert, Susanne Wiegratz, Balint Szilagyi, Andrew Blauvelt
Published 2024-09-01
Article -
10
Notalgia Paresthetica Dermatologist Report of Symptom Burden and Treatment: Results from a Physician Survey by Brian S. Kim, Sonja Ständer, Kenji Kabashima, Jennifer A. Mohawk, Sherri So, Joana Goncalves, Nilam Shah, Catherine Munera, Joseph C. Punzalan, Romelia Argudo, Mark Lebwohl
Published 2024-09-01
Article -
11
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel by Joshua Burshtein, Milaan Shah, Danny Zakria, Benjamin Lockshin, Jeff Crowley, Joseph F. Merola, Ken Gordon, Mona Shahriari, Neil J. Korman, Raj Chovatiya, Robert Kalb, Mark Lebwohl
Published 2024-02-01
Article -
12
-
13
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials by Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, Mark Lebwohl, Alice B. Gottlieb, Philip J. Mease, Atul Deodhar, Weibin Bao, Meryl Mendelson, Brian Porter, Deepa Chand, Victor Dong
Published 2024-03-01
Article -
14
Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Stu... by Paolo Gisondi, Alice B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M. López Pinto, Nicola Tilt, Mark Lebwohl
Published 2023-05-01
Article -
15
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CI... by Paolo Gisondi, Alice B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M. López Pinto, Nicola Tilt, Mark Lebwohl
Published 2022-12-01
Article -
16
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years by John E. Harris, Amit G. Pandya, Mark Lebwohl, Iltefat H. Hamzavi, Pearl Grimes, Alice B. Gottlieb, Howard L. Sofen, Angela Y. Moore, Mingyue Wang, Deanna Kornacki, Kathleen Butler, David Rosmarin
Published 2024-12-01
Article -
17
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events by Mark Lebwohl, Atul Deodhar, Sergio Schwartzman, Carlo Salvarani, Meghan Feely McDonald, Natalia Bello, Elsie L. Grace, Elsa Inman, Andris Kronbergs, Marcus Ngantcha, Proton Rahman, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Andrew Blauvelt
Published 2025-01-01
Article -
18
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trial... by Atul Deodhar, Andrew Blauvelt, Mark Lebwohl, Meghan Feely, Andris Kronbergs, Nadezhda Eberhart, Danting Zhu, Elsa Inman, Elsie Grace, Thorsten Holzkaemper, Proton Rahman, Helena Marzo-Ortega, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Sergio Schwartzman
Published 2024-02-01
Article